NKTR Quote, Financials, Valuation and Earnings

Ironwood Pharmaceuticals, Inc. has a net margin of -301.29% compared to Nektar Therapeutics's net margin of 32.84%. Nektar Therapeutics's return on equity of -327.67% beat Ironwood Pharmaceuticals, Inc.'s return on equity of --.

Nektar Therapeutics has a consensus price target of $114.43, signalling upside risk potential of 203.69%. On the other hand Ironwood Pharmaceuticals, Inc. has an analysts' consensus of $3.17 which suggests that it could fall by -29.63%. Given that Nektar Therapeutics has higher upside potential than Ironwood Pharmaceuticals, Inc., analysts believe Nektar Therapeutics is more attractive than Ironwood Pharmaceuticals, Inc..

Nektar Therapeutics has a beta of 1.306, which suggesting that the stock is 30.624% more volatile than S&P 500. In comparison Ironwood Pharmaceuticals, Inc. has a beta of 0.185, suggesting its less volatile than the S&P 500 by 81.483%.

Nektar Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ironwood Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nektar Therapeutics pays -- of its earnings as a dividend. Ironwood Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Nektar Therapeutics quarterly revenues are $11.8M, which are smaller than Ironwood Pharmaceuticals, Inc. quarterly revenues of $122.1M. Nektar Therapeutics's net income of -$35.5M is lower than Ironwood Pharmaceuticals, Inc.'s net income of $40.1M. Notably, Nektar Therapeutics's price-to-earnings ratio is -- while Ironwood Pharmaceuticals, Inc.'s PE ratio is 29.13x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nektar Therapeutics is 38.85x versus 2.24x for Ironwood Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of -301.29% compared to Nektar Therapeutics's net margin of 31.72%. Nektar Therapeutics's return on equity of -327.67% beat Eli Lilly & Co.'s return on equity of 106.26%.

Nektar Therapeutics has a consensus price target of $114.43, signalling upside risk potential of 203.69%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,110.79 which suggests that it could grow by 6.97%. Given that Nektar Therapeutics has higher upside potential than Eli Lilly & Co., analysts believe Nektar Therapeutics is more attractive than Eli Lilly & Co..

Nektar Therapeutics has a beta of 1.306, which suggesting that the stock is 30.624% more volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.348, suggesting its less volatile than the S&P 500 by 65.185%.

Nektar Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.58% to investors and pays a quarterly dividend of $1.50 per share. Nektar Therapeutics pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 44.39% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Nektar Therapeutics quarterly revenues are $11.8M, which are smaller than Eli Lilly & Co. quarterly revenues of $17.6B. Nektar Therapeutics's net income of -$35.5M is lower than Eli Lilly & Co.'s net income of $5.6B. Notably, Nektar Therapeutics's price-to-earnings ratio is -- while Eli Lilly & Co.'s PE ratio is 51.36x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nektar Therapeutics is 38.85x versus 15.93x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Lyell Immunopharma, Inc. has a net margin of -301.29% compared to Nektar Therapeutics's net margin of -258973.33%. Nektar Therapeutics's return on equity of -327.67% beat Lyell Immunopharma, Inc.'s return on equity of -86.7%.

Nektar Therapeutics has a consensus price target of $114.43, signalling upside risk potential of 203.69%. On the other hand Lyell Immunopharma, Inc. has an analysts' consensus of $29.67 which suggests that it could grow by 24.86%. Given that Nektar Therapeutics has higher upside potential than Lyell Immunopharma, Inc., analysts believe Nektar Therapeutics is more attractive than Lyell Immunopharma, Inc..

Nektar Therapeutics has a beta of 1.306, which suggesting that the stock is 30.624% more volatile than S&P 500. In comparison Lyell Immunopharma, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Nektar Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lyell Immunopharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nektar Therapeutics pays -- of its earnings as a dividend. Lyell Immunopharma, Inc. pays out -- of its earnings as a dividend.

Nektar Therapeutics quarterly revenues are $11.8M, which are larger than Lyell Immunopharma, Inc. quarterly revenues of $15K. Nektar Therapeutics's net income of -$35.5M is higher than Lyell Immunopharma, Inc.'s net income of -$38.8M. Notably, Nektar Therapeutics's price-to-earnings ratio is -- while Lyell Immunopharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nektar Therapeutics is 38.85x versus 86,158.63x for Lyell Immunopharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Rigel Pharmaceuticals, Inc. has a net margin of -301.29% compared to Nektar Therapeutics's net margin of 40.17%. Nektar Therapeutics's return on equity of -327.67% beat Rigel Pharmaceuticals, Inc.'s return on equity of 273.99%.

Nektar Therapeutics has a consensus price target of $114.43, signalling upside risk potential of 203.69%. On the other hand Rigel Pharmaceuticals, Inc. has an analysts' consensus of $51.60 which suggests that it could grow by 37.67%. Given that Nektar Therapeutics has higher upside potential than Rigel Pharmaceuticals, Inc., analysts believe Nektar Therapeutics is more attractive than Rigel Pharmaceuticals, Inc..

Nektar Therapeutics has a beta of 1.306, which suggesting that the stock is 30.624% more volatile than S&P 500. In comparison Rigel Pharmaceuticals, Inc. has a beta of 1.110, suggesting its more volatile than the S&P 500 by 11.007%.

Nektar Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rigel Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nektar Therapeutics pays -- of its earnings as a dividend. Rigel Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Nektar Therapeutics quarterly revenues are $11.8M, which are smaller than Rigel Pharmaceuticals, Inc. quarterly revenues of $69.5M. Nektar Therapeutics's net income of -$35.5M is lower than Rigel Pharmaceuticals, Inc.'s net income of $27.9M. Notably, Nektar Therapeutics's price-to-earnings ratio is -- while Rigel Pharmaceuticals, Inc.'s PE ratio is 6.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nektar Therapeutics is 38.85x versus 2.44x for Rigel Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.